Publications by authors named "Sara Naldini"
A real-life pediatric experience of Crohn's disease exclusion diet at disease onset and in refractory patients.
J Pediatr Gastroenterol Nutr
September 2024
Objectives: We aimed to appraise the real-life efficacy of Crohn's disease exclusion diet (CDED) coupled with partial enteral nutrition (PEN) in inducing clinical and biochemical remission at disease onset and in patients with loss of response to biologics and immunomodulators.
Methods: We retrospectively gathered data of patients aged less than 18 years of age with a diagnosis of Crohn's disease (CD), who received CDED coupled with PEN at a tertiary level pediatric inflammatory bowel disease center.
Results: Sixty-six patients were identified.
Background: The study aimed to assess the longitudinal impact of endoscopic healing (EH) and histological healing (HH) in a cohort of paediatric patients affected by ulcerative colitis (UC).
Methods: This was a retrospective single-centre longitudinal study. 86 children with UC who underwent endoscopic re-assessment while in clinical and biochemical remission were included.
Background: The aim of the present study was to investigate outcomes of anti-TNF-alpha (ATA) withdrawal in selected pediatric patients with inflammatory bowel disease who achieved clinical remission and mucosal and histological healing (MH and HH).
Methods: A retrospective analysis was performed on children and adolescents affected by Crohn disease (CD) and ulcerative colitis (UC) who were followed up at 2 tertiary referral centers from 2008 through 2018. The main outcome measure was clinical relapse rates after ATA withdrawal.
Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.
Inflamm Bowel Dis
January 2022
Article Synopsis
- The study aimed to evaluate the effectiveness and safety of SB5 in patients with inflammatory bowel disease (IBD) who were either new to treatment or switched from the original adalimumab (ADA).
- In the naïve group, 60.42% achieved remission after 12 months, while the switching group had a higher remission rate of 89.02%.
- Although 36.3% of patients experienced side effects, mainly injection site pain, no new antidrug antibodies developed in those who switched, indicating that SB5 is a viable treatment option for IBD.
Article Synopsis
- - The study assessed mucosal healing (MH) and histological healing (HH) outcomes in pediatric patients with inflammatory bowel disease (IBD) treated with anti-TNF-alpha agents at two centers.
- - Out of 170 patients, only 41% of those with Crohn's disease (CD) and 53.6% with ulcerative colitis (UC) achieved MH, while 33.3% of CD and 39.3% of UC patients achieved HH, indicating lower rates than previous studies.
- - Factors like achieving remission at the end of treatment were linked to higher MH and HH rates, while treatment with adalimumab showed lower rates of these healing outcomes, highlighting variability in patient responses
Bowel Ultrasound Scan Predicts Corticosteroid Failure in Children With Acute Severe Colitis.
J Pediatr Gastroenterol Nutr
July 2020
Background And Objective: Acute severe colitis (ASC) is a potentially life-threatening event. Optimal timing for second-line treatment in children is mainly based on the clinical score Pediatric Ulcerative Colitis Activity Index. The aim of our study was to evaluate the potential role of bowel ultrasound scan (BUS) in predicting the need of second-line therapy in ASC.
View Article and Find Full Text PDFBackground: Trichorhinophalangeal syndrome (TRPS) is a rare autosomal dominant disorder caused by defects involving the TRPS1 gene. It exhibits distinctive craniofacial, ectodermal and skeletal abnormalities, such as sparse hair, bulbous nasal tip and short deformed fingers, with extremely variable expressivity.
Case Presentation: We report the case of a 17 months old girl, who presented growth retardation and dysmorphic features.